Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
3.
Neuroradiology ; 62(6): 733-739, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32008046

ABSTRACT

PURPOSE: Recent randomized-controlled clinical trials have provided preliminary evidence for expanding the time window of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients by applying certain neuroimaging criteria. We prospectively assessed the potential eligibility for IVT in the extended time window (4.5-9 h) among consecutive AIS patients treated in a comprehensive stroke center during a nine-month period. METHODS: Potential eligibility for IVT in the extended time window was evaluated by using inclusion criteria from the EXTEND trial. All patients were underwent baseline emergent neurovascular imaging using either computed tomography angiography/computed tomography perfusion (CTA/CTP) or magnetic resonance angiography/magnetic resonance perfusion (MRA/MRP). Images were post processed by the automated software RAPID. RESULTS: Our study population consisted of 317 AIS patients, and, among them, 31 (9.8 %) patients were presented in the time window of 4.5-9 h. Seven patients (2.2 %) fulfilled the EXTEND neuroimaging criteria. Four patients (1.3 %) were treated with IVT because they fulfilled both clinical and neuroimaging EXTEND criteria. Patients eligible for EXTEND neuroimaging criteria had no ischemic core lesion, whereas the mean volume of critical hypoperfusion was relatively small (17.0 ± 11.8 ml). There was no hemorrhagic complication in any of the patients treated with IVT. The median mRS score at three months was 0 (range: 0-3) among patients who were eligible for EXTEND neuroimaging criteria. CONCLUSION: Our everyday clinical practice experience suggests 9.8 % of consecutive AIS patients present in the 4.5-9 h window and 2.2 % adhere to EXTEND neuroimaging eligibility criteria for IVT. Only 1.3% of AIS is eligible for IVT according to EXTEND neuroimaging and clinical eligibility criteria.


Subject(s)
Ischemic Stroke/drug therapy , Patient Selection , Thrombolytic Therapy/methods , Time-to-Treatment , Aged , Aged, 80 and over , Female , Humans , Image Interpretation, Computer-Assisted , Ischemic Stroke/diagnostic imaging , Male , Neuroimaging/methods , Prospective Studies , Risk Factors
4.
Neurologist ; 24(6): 180-182, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31688709

ABSTRACT

INTRODUCTION: Tenecteplase has recently been studied as an alternative thrombolytic agent in acute stroke, with a possible superior effect in achieving reperfusion of large intracranial vessels. CASE REPORT: A 90-year-old female patient was admitted to our stroke unit because of acute onset of dysarthria, left-sided neglect, and hemiparesis. Brain computed tomography (CT) coupled with CT angiography and CT perfusion (postprocessed with the use of RAPID software) demonstrated right proximal middle cerebral artery occlusion with a large penumbra/small ischemic core pattern. The patient was subsequently treated with bolus tenecteplase infusion (0.25 mg/kg). Mechanical thrombectomy was abandoned because the patient has rapidly improved. The patient was discharged to her own home 4 days later with no neurological deficit and functionally independent (modified Rankin scale of 0). CONCLUSION: This case exemplifies the potential of tenecteplase in achieving swift reperfusion in patients with large vessel occlusion associated with a substantial mismatch penumbral pattern.


Subject(s)
Brain Ischemia/drug therapy , Fibrinolytic Agents/therapeutic use , Infarction, Middle Cerebral Artery/drug therapy , Mechanical Thrombolysis/methods , Tenecteplase/therapeutic use , Aged, 80 and over , Brain Ischemia/complications , Female , Humans , Infarction, Middle Cerebral Artery/complications , Treatment Outcome
5.
Neurologist ; 24(5): 146-149, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31478997

ABSTRACT

INTRODUCTION: Fabry is a rare X-linked recessive genetic disease caused by α-galactosidase A deficiency. Cerebrovascular events occur in ∼13% of patients, whereas stroke may be the presenting clinical manifestation. There are very limited case reports of tissue plasminogen activator administration for acute ischemic stroke in patients with Fabry disease. CASE REPORT: A 46-year-old man presented with right-sided hemiparesis with a National Institutes of Health Stroke Scale score of 3. Brain computed tomography showed a hyperdense lesion resembling carvenous angioma. The patient received intravenous thrombolysis 265 minutes after symptom onset, with clinical improvement (discharge National Institutes of Health Stroke Scale score of 1). Brain magnetic resonance imaging disclosed acute thalamic infarction, cavernous angioma, and multiple cerebral microbleeds. The presence of skin angiokeratomas and cardiac hypertrophy prompted further positive investigation for Fabry disease (nondetectable α-galactosidase activity, excessively elevated lyso-Gb3, and pathogenic deletion in the GLA gene). CONCLUSION: The present case supports the scarce data underscoring the safety of intravenous thrombolysis for acute ischemic stroke in Fabry disease patients even when cerebral microbleeds are present.


Subject(s)
Brain Ischemia/drug therapy , Fabry Disease/complications , Stroke/drug therapy , Thrombolytic Therapy/methods , Tissue Plasminogen Activator/therapeutic use , Administration, Intravenous , Brain/diagnostic imaging , Brain Ischemia/complications , Brain Ischemia/diagnosis , Fabry Disease/diagnosis , Humans , Male , Middle Aged , Stroke/complications , Stroke/diagnosis , Tissue Plasminogen Activator/administration & dosage , Treatment Outcome
6.
Postgrad Med ; 131(7): 490-495, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31408393

ABSTRACT

Objective: Familial Multiple Sclerosis (fMS) is reported to have distinct clinical and imaging characteristics in comparison to the sporadic disease (sMS). Nevertheless, the genetic/immunogenetic profile of fMS has never been investigated in depth, so far. In this study, we examined differences of HLA-DRB1 allelic frequencies between 57 fMS and 141 sMS Hellenic patients, with reference to 246 previously genotyped healthy controls (HCs). Patients and Methods: All patients underwent medical interview and DRB1 genotyping, using a low-resolution SSOP technique. Statistical analyses were performed using SPSS v.21.0 software, with significance set at 0.05, and p value corrected according to the Benjamini-Yekutieli method. Results: 29 fMS cases had at least one 1st degree relative affected (fMS 1st), while the rest had at least one 2nd or 3rd degree relative affected (fMS 2nd/3rd). Parent-of-origin effects were observed, with the prevalence of maternal inheritance. Frequency of DRB1*15 was significantly increased in fMS and sMS, in comparison to HCs (p = 0.002 and <0.001, respectively). After fMS stratification, this result was mainly attributed to the fMS 2nd/3rd subgroup. DRB1*11 frequency was significantly decreased only in sMS (p < 0.001) with fMS approximating HCs' frequency, especially for the fMS 1st subgroup. Heterozygosity was favored over homozygosity in all groups. Conclusion: We propose possible HLA-DRB1 allelic distribution differences between fMS and sMS, which become more apparent as proximity of affected relative/-es in fMS increases, supporting a rather degraded role of DRB1 alleles in fMS HLA/immunogenetics and indicating the concomitant implication of other HLA and non-HLA polymorphisms.


Subject(s)
HLA-DRB1 Chains/genetics , Multiple Sclerosis/genetics , Adult , Family , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Greece , Humans , Male , Middle Aged , Phenotype , Young Adult
7.
J Neuroimaging ; 29(3): 309-322, 2019 05.
Article in English | MEDLINE | ID: mdl-30702779

ABSTRACT

Acute multi-territory, embolic cerebral infarctions are often associated with serious underlying clinical conditions including the presence of highly "active" emboligenic sources causing that in turn may result in high early recurrence rates. Prompt diagnosis, risk stratification, and treatment are substantial for the prevention of subsequent embolization that would result in further clinical deterioration. Among other clinical investigations, transcranial Doppler (TCD) monitoring is highly efficacious for the detection of microembolic signals (MES) that correspond to microthrombi entering the intracranial circulation. The presence and burden of MES, especially in multiple intracranial arteries, is clearly associated with an increased risk of symptomatic, recurrent embolization, and thus can justify a more aggressive treatment approach (clopidogrel load followed by dual antiplatelet therapy or alternatively therapeutic dose of low-molecular-weight heparin). In this narrative review, we discuss the most important causes of multi-territory embolic ischemic strokes and also underscore the utility of TCD as a noninvasive tool for the diagnosis, risk stratification, and treatment.


Subject(s)
Intracranial Embolism/diagnostic imaging , Stroke/diagnostic imaging , Ultrasonography, Doppler, Transcranial , Humans , Intracranial Embolism/complications , Stroke/etiology
8.
Neurocase ; 24(4): 188-194, 2018 08.
Article in English | MEDLINE | ID: mdl-30293488

ABSTRACT

Anti-NMDA receptor (NMDA-r) encephalitis is a relatively rare cause of autoimmune encephalitis with divergent clinical presentations. We report a case of an adult patient with anti-NMDA-r encephalitis presenting with isolated, abrupt-onset aphasia. Her condition remained unaltered over a period of 6 months. The patients' electroencephalogram findings were typical for NMDA-r encephalitis; however, her magnetic resonance imaging and cerebrospinal fluid analysis were normal. She responded well to immunotherapy, and aphasia eventually resolved. The natural course of the present case contradicts the rapidly progressive nature of typical NMDA-r encephalitis. Furthermore, it broadens the clinical spectrum of anti-NMDA-r encephalitis, to incorporate isolated, nonprogressive aphasia.


Subject(s)
Anti-N-Methyl-D-Aspartate Receptor Encephalitis/complications , Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis , Aphasia/complications , Aphasia/diagnosis , Adult , Brain/physiopathology , Electroencephalography , Female , Humans , Neuropsychological Tests
9.
Clin Neurol Neurosurg ; 173: 144-149, 2018 10.
Article in English | MEDLINE | ID: mdl-30125837

ABSTRACT

OBJECTIVE: Few studies are available worldwide concerning clinical, imaging and genetic/immunogenetic profile of familial multiple sclerosis (fMS). Recent but not systematic data concerning fMS, without direct comparison to sporadic MS (sMS) drove our aim towards further research in the field, given the total lack of information for the Greek population as well. Thus, in this case-control study we examined the clinical and imaging characteristics of 102 fMS-patients, compared to 282 patients suffering sMS. PATIENTS AND METHODS: Patients recruited underwent medical interview (demographic, clinical and family history data collected). They were also assessed for disability and their MRI-scans were analyzed for lesion distribution. Statistical analyses were performed using SPSS v.21.0 software. RESULTS: 49% of unrelated fMS cases had at least one 1st degree relative affected, while the rest had also at least one relative with MS, 3rd degree or closer. Only the former subgroup (1st degree relative) and not the entire fMS sample, had significantly younger age at onset (AAO) compared to sMS cases (mean AAO 28.08 vs 31.33 years, p = 0.036). AAO anticipation was noted in younger generation fMS patients (mean AAO 24.67 years in younger generation vs 37 years in older generation, p = 0.001). With regard to our MRI findings, subcortical lesions were less frequent in fMS (71% in fMS vs 81.9% in sMS patients, p = 0.028), whereas cervical cord lesions more frequent (93% in fMS vs 79.9% in sMS patients, p = 0.033, only in the 1st degree relative subgroup). Double vision was a less common first symptom in fMS (4.1% in fMS vs 14.8% in sMS patients, p = 0.005). 1st degree relatives of fMS patients were more often diagnosed with Hashimoto's (8.9% in fMS relatives vs 3.3% in sMS relatives, p = 0.033). CONCLUSION: Younger AAO and different lesion distribution in brain and possibly spinal cord was observed in fMS in comparison to sMS patients. The hypothesis of increased genetic burden in fMS could offer some explanation for these differences, which needs though further validation as a next step, through genetic/immunogenetic testing in larger cohorts, of different ethnic groups.


Subject(s)
Brain/diagnostic imaging , Genetic Predisposition to Disease , Multiple Sclerosis/diagnostic imaging , Multiple Sclerosis/epidemiology , Adolescent , Adult , Age of Onset , Aged , Brain/pathology , Case-Control Studies , Female , Greece , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/genetics , Spinal Cord/pathology , Young Adult
10.
J Neuroimaging ; 28(3): 239-251, 2018 05.
Article in English | MEDLINE | ID: mdl-29334161

ABSTRACT

Carotid artery disease (CAD) is a common cause of ischemic stroke with high rates of recurrence. Carotid endarterectomy (CEA) or carotid artery stenting (CAS) are highly recommended for the secondary prevention of symptomatic CAD during the first 14 days following the index event of transient ischemic attack or minor stroke. CEA or CAS may also be offered in selected cases with severe asymptomatic stenosis. Herein, we review the utility of neurosonology in the diagnosis and pre-/peri-interventional assessment of CAD patients who undergo carotid revascularization procedures. Carotid ultrasound may provide invaluable information on plaque echogenicity, ulceration, risk of thrombosis, and rupture. Transcranial Doppler or transcranial color-coded sonography may further assist by mapping collateral circulation, evaluating the impairment of vasomotor reactivity, detecting microembolization, or reperfusion hemorrhage in real time. Neurosonology examinations are indispensable bedside tools assisting in the diagnosis, risk stratification, peri-interventional monitoring, and follow-up of patients with CAD.


Subject(s)
Carotid Arteries/diagnostic imaging , Carotid Artery Diseases/diagnostic imaging , Carotid Stenosis/diagnostic imaging , Ischemic Attack, Transient/diagnostic imaging , Stroke/diagnostic imaging , Ultrasonography, Doppler, Transcranial , Carotid Arteries/surgery , Carotid Artery Diseases/complications , Carotid Artery Diseases/surgery , Carotid Stenosis/complications , Carotid Stenosis/surgery , Endarterectomy, Carotid , Humans , Ischemic Attack, Transient/etiology , Stroke/etiology , Treatment Outcome
11.
Neurol Sci ; 39(2): 359-364, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29196955

ABSTRACT

Differential diagnosis of progressive supranuclear palsy (PSP) and the parkinsonian variant of multiple system atrophy (MSA-P) from Parkinson's disease (PD) can be difficult, particularly in atypical cases or early in the disease course. The Magnetic Resonance Parkinsonism Index (MRPI) utilizes linear and surface (planimetry) measurements and has been proposed as a dual MRI biomarker, with high values indicative of PSP and low values of MSA. The aim of this study was to examine the utility of simple linear MRI brainstem measurements, without the use of MRI planimetry, in the diagnosis of patients with Parkinsonism and compare them to the MRPI. A total of 51 patients (PSP: 24, MSA-P: 9, PD: 18) and 15 healthy controls were included. Simple linear MRI distances of brainstem structures were measured. These included midbrain and pons diameters as well as superior cerebellar peduncle (SCP) and middle cerebellar peduncle (MCP) widths. All relevant indices, including ratios and products, were also calculated. The SCP by midbrain product (SCP × midbrain) provided improved sensitivity (100 vs. 91%) and identical specificity (98%) for the diagnosis of PSP, compared to the MRPI. Neither the MRPI nor any of the linear measurements were able to discriminate MSA-P from PD. The SCP by midbrain product is a novel, potent MRI biomarker for PSP.


Subject(s)
Brain Stem/diagnostic imaging , Magnetic Resonance Imaging/methods , Multiple System Atrophy/diagnostic imaging , Parkinsonian Disorders/diagnostic imaging , Supranuclear Palsy, Progressive/diagnostic imaging , Aged , Female , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Retrospective Studies , Severity of Illness Index , Statistics, Nonparametric
12.
J Neurol Sci ; 382: 91-95, 2017 Nov 15.
Article in English | MEDLINE | ID: mdl-29111028

ABSTRACT

INTRODUCTION: Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aß42, tau protein - τT and phosphorylated tau protein - τP-181) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. The aim of this study was to analyze the CSF biochemical profile of patients with Parkinsonism. METHODS: We analyzed the CSF biomarker profile (Aß42, τT, τP-181, α-syn) and all relevant ratios in 68 patients with Parkinsonism (19 PSP, 15 MSA, 17 CBD, 17 PD) and 18 controls, diagnosed by latest established diagnostic criteria. RESULTS: CBD patients exhibited elevated τT and decreased Aß42 compared to the other groups. Five CBD, one PSP patient and one control had a typical AD CSF profile. After exclusion of these patients, the τT/Aß42 ratio was significantly elevated in MSA patients compared to PD patients and provided excellent specificity and adequate sensitivity in their differential diagnosis. CONCLUSION: CSF biochemical profile analysis is important in distinguishing AD patients with a CBS phenotype from non-AD CBS patients. The τT/Aß42 ratio is useful in the differential diagnosis of MSA from PD.


Subject(s)
Amyloid beta-Peptides/cerebrospinal fluid , Multiple System Atrophy/cerebrospinal fluid , Parkinson Disease/cerebrospinal fluid , Peptide Fragments/cerebrospinal fluid , Supranuclear Palsy, Progressive/cerebrospinal fluid , alpha-Synuclein/cerebrospinal fluid , tau Proteins/cerebrospinal fluid , Aged , Biomarkers/cerebrospinal fluid , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Prospective Studies , ROC Curve , Registries
14.
SAGE Open Med Case Rep ; 5: 2050313X17720101, 2017.
Article in English | MEDLINE | ID: mdl-28781879

ABSTRACT

Pantothenate-kinase-associated neurodegeneration is the most common autosomal recessive form of neurodegeneration with brain iron accumulation. Less than 100 mutations in PANK2 gene (20p13) are responsible for classic and atypical cases. We report here the first Greek case of atypical pantothenate-kinase-associated neurodegeneration, confirmed by molecular analysis that revealed two trans-acting mutations. Our findings highlight the possible role of rare variants contributing to disease risk and possibly to variable clinical phenotype.

15.
Neurologist ; 22(3): 90-91, 2017 May.
Article in English | MEDLINE | ID: mdl-28471898

ABSTRACT

INTRODUCTION: Recognizing new-territory ischemic stroke as an uncommon complication of intravenous thrombolysis is very important as it can lead to neurological deterioration during tissue-plasminogen-activator infusion. CASE REPORT: We report a case of an 80-year-old patient that has been treated with intravenous thrombolysis for right middle cerebral artery acute ischemic stroke. During infusion he had an abrupt neurological deterioration that proved to be a distal embolization of an asymptomatic non-occluding tip-of-the-basilar thrombus to the territory of left posterior cerebral artery that has been missed by the treating neurologist and radiologist in the pretreatment computed tomography angiography. In the thrombectomy that followed, only the right carotid artery has been catheterized and only the right middle cerebral artery was successfully recanalized, leaving the left posterior cerebral artery occlusion untreated. CONCLUSIONS: This case highlights that the use of thrombectomy in clinical practice provides an effective therapeutic option for large vessel occlusion in this setting. However, high clinical suspicion for this rare complication is mandatory to proceed to correct diagnosis and treatment.


Subject(s)
Brain Ischemia/drug therapy , Stroke/drug therapy , Thrombolytic Therapy , Tissue Plasminogen Activator/adverse effects , Administration, Intravenous , Aged, 80 and over , Brain Ischemia/complications , Humans , Male , Stroke/complications , Tissue Plasminogen Activator/administration & dosage , Tissue Plasminogen Activator/therapeutic use
18.
J Neuroimaging ; 26(4): 377-82, 2016 07.
Article in English | MEDLINE | ID: mdl-27171686

ABSTRACT

BACKGROUP AND PURPOSE: There are limited data regarding the diagnostic yield of transcranial color-coded Doppler (TCCD) in acute encephalitis. We present our preliminary observations of consecutive ultrasound evaluations in 2 patients with acute encephalitis and we review the possible diagnostic role of TCCD in such cases. METHODS: We describe two cases of acute encephalitis that presented with aphasia and confusion and underwent repeat TCCD evaluation at baseline and after 48 hours in both patients. We also critically review the current literature regarding potential TCCD applications in acute central nervous system infections. RESULTS: Serial TCCD evaluations revealed the following triad of abnormal findings in both patients: (i) elevated pulsatility index (PI) in the left middle cerebral artery (M1 MCA) at baseline (>1.2), (ii) increased PI in left M1 MCA by >25% in comparison to right M1 MCA, and (iii) decrease in PI in left M1 MCA by >25% at the follow-up evaluation at 48 hours. The decrease in PI in left M1 MCA coincided with symptom improvement in both patients. DISCUSSION: The focal transient increase in left M1 MCA PI may be attributed to focally increased intracranial pressure or peripheral vasospasm of distal left MCA branches. Since there are limited reports in the literature concerning TCCD evaluation of patients with central nervous system infections, our preliminary findings require independent confirmation in a larger series of patients.


Subject(s)
Acute Febrile Encephalopathy/diagnostic imaging , Encephalitis, Varicella Zoster/diagnostic imaging , Meningitis, Listeria/diagnostic imaging , Ultrasonography, Doppler, Color/trends , Ultrasonography, Doppler, Transcranial/trends , Aged , Aged, 80 and over , Female , Follow-Up Studies , Forecasting , Humans , Magnetic Resonance Imaging , Middle Cerebral Artery/diagnostic imaging , Pulsatile Flow/physiology , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...